Influence of endothelin-1 and nitric oxide on left ventricular remodelling in patients on peritoneal dialysis

Damir Rebic1, Senija Rasic, Velma Rebic

  • 1Clinic for Nephrology, Clinical Center of University of Sarajevo , Sarajevo , Bosnia and Herzegovina and.

Renal Failure
|September 25, 2013
PubMed

Insights

Endothelin-1 (ET-1) and nitric oxide (NO) levels are linked to left ventricular remodeling in patients undergoing peritoneal dialysis (PD). Changes in ET-1 and NO correlate with improvements in left ventricular hypertrophy after PD treatment.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Left ventricular hypertrophy (LVH) is a common cardiac issue in chronic dialysis patients.
  • The study investigates the role of endothelin-1 (ET-1) and nitric oxide (NO) in LV remodeling in peritoneal dialysis (PD) patients.

Purpose of the Study:

  • To determine the association between ET-1, NO, and echocardiographic parameters in PD patients.
  • To assess the participation of ET-1 and NO in left ventricular (LV) remodeling during PD treatment.

Main Methods:

  • Prospective longitudinal study of 40 PD patients.
  • Measured serum ET-1 and NO levels at baseline and 12 months, alongside echocardiography.
  • Linear regression analysis identified independent predictors of LV mass index.

Main Results:

  • Serum ET-1 decreased and NO increased significantly after 12 months of PD (p < 0.01).
  • LVH was prevalent at baseline (72.5%), with significant reduction in LV mass index after treatment (p < 0.001).
  • ET-1 and NO were independent predictors of LV mass index.

Conclusions:

  • ET-1 and NO are independently associated with left ventricular remodeling in PD patients.
  • These vasoactive substances play a crucial role in cardiac structural changes during PD therapy.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...